Literature DB >> 10974377

Palliative radiotherapy practice within Western European countries: impact of the radiotherapy financing system?

Y Lievens1, W Van den Bogaert, A Rijnders, G Kutcher, K Kesteloot.   

Abstract

PURPOSE: To analyze the reimbursement modalities for radiotherapy in the different Western European countries, as well as to investigate if these differences have an impact on the palliative radiotherapy practice for bone metastases.
MATERIALS AND METHODS: A questionnaire was sent to 565 radiotherapy centres included in the 1997 ESTRO directory. In this questionnaire the reimbursement strategy applied in the different centres was assessed, with respect to the use of a budget (departmental or hospital budget), case payment and/or fee-for-service reimbursement. The differences were analyzed according to country and to type and size of the radiotherapy centre.
RESULTS: A total of 170 centres (86% of the responders) returned the questionnaire. Most frequent is budget reimbursement: some form of budget reimbursement is found in 69% of the centres, whereas 46% of the centres are partly reimbursed through fee-for-service and 35% through case payment. The larger the department, the more frequent the reimbursement through a budget or a case payment system and the less the importance of fee-for-service reimbursement (chi(2): P=0.0012; logit: P=0.0055). Whereas private centres are almost equally reimbursed by fee-for-service financing as by budget or case payment, radiotherapy departments in university hospitals receive the largest part of their financial resources through a budget or by case payment (83%) (chi(2): P=0.002; logit: P=0.0073). A correlation between the country and the radiotherapy reimbursement system was also demonstrated (P=0.002), radiotherapy centres in Spain, the Netherlands and the United Kingdom being almost entirely reimbursed through a budget and/or case payment and centres in Germany and Switzerland mostly through a fee-for-service system. In budget and case payment financing lower total number of fractions and lower total dose (chi(2): P=0.003; logit: P=0.0120) as well as less shielding blocks (chi(2): P=0.003; logit: P=0.0066) are used. A same tendency is found for the use of isodose calculations and field set-up, but without being statistically significant (P=0.264 and P=0.061 res.). The type of the centre and the reimbursement modality influence the fractionation regimen independently (P=0.0274). This is not the case for the centre size and the reimbursement, which were found to exert correlated effects on the fractionation schedule (P=0.1042).
CONCLUSION: Reimbursement systems seem to influence radiotherapy practice. One should therefore aim to develop reimbursement criteria that pursue to deliver, not only the best qualitative, but also the most cost-effective treatments to the patients.

Entities:  

Mesh:

Year:  2000        PMID: 10974377     DOI: 10.1016/s0167-8140(00)00214-0

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  14 in total

1.  Hypofractionated radiotherapy in the real-world setting: An international ESTRO-GIRO survey.

Authors:  Danielle Rodin; Bouchra Tawk; Osama Mohamad; Surbhi Grover; Fabio Y Moraes; Mei Ling Yap; Eduardo Zubizarreta; Yolande Lievens
Journal:  Radiother Oncol       Date:  2021-01-14       Impact factor: 6.280

Review 2.  Palliative radiotherapy for bone metastases from lung cancer: Evidence-based medicine?

Authors:  Alysa Fairchild
Journal:  World J Clin Oncol       Date:  2014-12-10

3.  A survey of patterns of practice on palliative radiation therapy for bone metastasis in Korea.

Authors:  Yoonsun Chung; Woong Sub Koom; Yong Chan Ahn; Hee-Chul Park; Hak Jae Kim; Sang Min Yoon; Sangjin Shin; Yoon Jae Lee
Journal:  J Cancer Res Clin Oncol       Date:  2013-10-10       Impact factor: 4.553

4.  Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study.

Authors:  Aileen B Chen; Angel Cronin; Jane C Weeks; Elizabeth A Chrischilles; Jennifer Malin; James A Hayman; Deborah Schrag
Journal:  J Clin Oncol       Date:  2013-01-07       Impact factor: 44.544

5.  Prevalence and Predictors of Inappropriate Delivery of Palliative Thoracic Radiotherapy for Metastatic Lung Cancer.

Authors:  Matthew Koshy; Renuka Malik; Usama Mahmood; Zain Husain; Ralph R Weichselbaum; David J Sher
Journal:  J Natl Cancer Inst       Date:  2015-09-30       Impact factor: 13.506

6.  Patterns of practice in the prescription of palliative radiotherapy for the treatment of bone metastases at the Rapid Response Radiotherapy Program between 2005 and 2012.

Authors:  N Thavarajah; L Zhang; K Wong; G Bedard; E Wong; M Tsao; C Danjoux; E Barnes; A Sahgal; K Dennis; L Holden; N Lauzon; E Chow
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

7.  Considerations for Quality Improvement in Radiation Oncology Therapy for Patients with Uncomplicated Painful Bone Metastases.

Authors:  Anne M Walling; Phillip J Beron; Tania Kaprealian; Patrick A Kupelian; Neil S Wenger; Susan A McCloskey; Christopher R King; Michael Steinberg
Journal:  J Palliat Med       Date:  2017-02-23       Impact factor: 2.947

Review 8.  Review of patterns of practice and patients' preferences in the treatment of bone metastases with palliative radiotherapy.

Authors:  Nicole M E Bradley; Janice Husted; Michael Sai Lai Sey; Amna F Husain; Emily Sinclair; Kristin Harris; Edward Chow
Journal:  Support Care Cancer       Date:  2006-11-09       Impact factor: 3.359

Review 9.  International patterns of practice in radiotherapy for bone metastases: A review of the literature.

Authors:  Rachel McDonald; Edward Chow; Henry Lam; Leigha Rowbottom; Hany Soliman
Journal:  J Bone Oncol       Date:  2014-11-07       Impact factor: 4.072

10.  Evaluating the attendance of medical staff and room occupancy during palliative radiotherapy.

Authors:  Irenäus A Adamietz; Oliver Micke; Wolfgang Popp; Horst Sack
Journal:  Strahlenther Onkol       Date:  2014-05-13       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.